Dermavant Sciences
United States
35 articles with Dermavant Sciences
-
Clinical Catch-Up: August 24-28
8/31/2020
As August wraps up, there were still clinical trial announcements, although fewer than earlier this summer. Here’s a look. -
The trials were identical, multi-center, randomized, vehicle-controlled, double-blind, parallel studies that evaluated tapinarof cream, 1% in adults with plaque psoriasis.
-
Dermavant Reports Positive Phase 3 Results for Tapinarof Cream in Adult Patients with Plaque Psoriasis
8/26/2020
- Primary Endpoints Met in PSOARING 1 and PSOARING 2 Clinical Trials (P-values <0.0001) - - Up to 80% of Patients Achieved ≥1-Grade Improvement in PGA - - All Secondary Endpoints Achieved in Both Trials, Including PASI75 - - Tapinarof is a Potential First-in-Class Psoriasis Treatment with a Novel Mechanism of Action - - To Date, Over 2,200 Subjects Have Enrolled in 17 Clinical Trials of Tapinarof
-
Dermavant Announces Publication in JAAD of Secondary Efficacy and Patient-Reported Outcomes in Phase 2b Clinical Trial of Tapinarof Cream for the Treatment of Atopic Dermatitis
6/16/2020
Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced the publication of secondary efficacy and patient-reported outcomes from its Phase 2b randomized clinical trial of tapinarof cream for the treatment of atopic dermatitis in The Journal of the American Academy of Dermatology
-
Clinical Catch-Up: June 8-12
6/15/2020
It was a fairly busy week with clinical trial updates and announcements. Here’s a look. -
BioSpace Global Roundup, June 11
6/11/2020
Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses. -
Dermavant Completes Patient Enrollment for Long-Term Safety Study of Tapinarof in Adult Patients with Psoriasis
6/9/2020
Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced the completion of patient enrollment in the company’s long-term safety study of tapinarof, a potential first-in-class, once-daily topical therapeutic aryl hydrocarbon receptor modulating agent (TAMA), in adult patients diagnosed with plaque psoriasis.
-
Dermavant Completes Patient Enrollment for Long-Term Safety Study of Tapinarof in Adult Patients with Psoriasis
6/9/2020
Tapinarof is a Potential First-in-Class Psoriasis Treatment with a Novel Mechanism of Action
-
Clinical Catch-Up: May 25-29
6/1/2020
In the lead-up to the ASCO Annual Meeting, companies were presenting some of their trial data, while other companies were presenting news related to COVID-19 studies. Here’s a look. -
BioSpace Global Roundup, May 28
5/28/2020
Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses. -
Dermavant Announces Publication in JAAD of Secondary Efficacy and Patient-Reported Outcomes in Phase 2b Clinical Trial of Tapinarof Cream for the Treatment of Plaque Psoriasis
5/26/2020
Dermavant Sciences announced the publication of secondary efficacy and patient-reported outcomes from the Phase 2b randomized clinical trial of tapinarof cream for the treatment of plaque psoriasis in The Journal of the American Academy of Dermatology, the peer-reviewed scientific publication of the American Academy of Dermatology 1.
-
Dermavant Completes Patient Enrollment for Two Phase 3 Clinical Trials of Tapinarof for the Treatment of Psoriasis
4/2/2020
Dermavant Sciences announced the completion of patient enrollment in the company’s PSOARING 1 and PSOARING 2 clinical trials of tapinarof, a potential first-in-class, once-daily topical therapeutic aryl hydrocarbon receptor modulating agent, in adult patients diagnosed with plaque psoriasis.
-
BioSpace Movers & Shakers, Jan. 24
1/24/2020
Pharma and life sciences companies strengthen their leadership and boards with this week's appointments. -
Dermavant Appoints Chris Chapman as Chief Commercial Officer
1/22/2020
Dermavant Sciences, a dermatology-focused subsidiary of Roivant Sciences, today announced the appointment of Chris Chapman as Chief Commercial Officer.
-
BioSpace Global Roundup, Jan. 16
1/16/2020
Companies from across the globe provide updates to their business and pipeline. -
Dermavant Enters into Exclusive License Agreement with JT for Development and Commercialization of Tapinarof in Japan
1/15/2020
JT and its subsidiary, Torii Pharmaceutical, receive rights to develop and commercialize tapinarof for psoriasis and atopic dermatitis in Japan
-
Dermavant Announces First Patient Dosed in Phase 2a Clinical Trial of Topical Dual JAK/Syk Inhibitor Cerdulatinib for Vitiligo
12/3/2019
Dermavant Sciences, a dermatology-focused subsidiary of Roivant Sciences, announced that the first patient has been dosed in its Phase 2a vitiligo clinical trial for topical cerdulatinib.
-
Dermavant Sciences Announces First Patient Dosed in PSOARING, its Pivotal Phase 3 Clinical Program for Tapinarof for the Topical Treatment of Plaque Psoriasis
6/5/2019
Dermavant Sciences, a dermatology-focused subsidiary of Roivant Sciences, today announced that the first patient has been dosed in its pivotal Phase 3 psoriasis clinical program, PSOARING, for its lead product candidate, tapinarof. Tapinarof is a therapeutic aryl hydrocarbon receptor modulating agent (TAMA) topical cream being developed by Dermavant for plaque psoriasis and atopic dermatitis
-
Dermavant Sciences Appoints Timothy S. Nelson and Kenneth E. Ludlum to Board of Directors
5/15/2019
Dermavant Sciences, a dermatology-focused subsidiary of Roivant Sciences, today announced that Timothy S. Nelson and Kenneth E. Ludlum have been appointed to Dermavant’s Board of Directors.
-
BioSpace Movers and Shakers: March 29
3/29/2019
Biotech and pharma companies bring on new talent to strengthen leadership teams and boards.